Share on
The 2017 Systems Biology Symposium
Boston, MA
Join us as we deep-dive into two of the biggest challenges in drug development today: Indication Prioritization and Target Identification.
At this year's Systems Biology Symposium, industry leaders will demonstrate how they're overcoming target identification failure as well as prioritizing indications to develop first-in-class, and best-in-class drugs.
Agenda
| 8.00 AM: | Registration and welcome break |
| 8.30 AM: | Introduction and opening remarks Chair: Matthew Wampole, PhD, Manager, Solutions Scientists, Clarivate Analytics |
| 9.00 AM: | CBDD (Computational Biology Methods for Drug Discovery) program scope, completed development and next steps Alexander Ivliev, Principal Research Scientist, Clarivate Analytics |
| 9.30 AM: | An integrative systems biology approach for prioritizing biomarkers and drug targets in complex diseases Rima Hajjo, Solution Scientist, Clarivate Analytics |
| 10.00 AM: | Morning break |
| 10.30 AM: | Evaluation of network algorithms across multiple data types and applications Abby Hill, Graduate Student, Massachusetts Institute of Technology |
| 11.00 AM: | Accelerate drug discovery with network approaches Kejie Li, Computational Biologist – Scientist, Biogen |
| 11.30 AM: | Systems biology approach to large scale systematic indication prioritization Marina Bessarabova, Sr. Director, Discovery and Translational Practice, Clarivate Analytics |
| 12.00 PM: | Networking lunch |
| 12.45 PM: | Inferring pathway activation from single cell transcriptome Mindy Zhang, Principal Scientist, Sanofi Genzyme |
| 1.15 PM: | The evolving landscape of drug discovery – discovery in an right-sourced model Madhu Nataranjan, Research Therapeutic Area Head, Ophthalmics & Complement Biology, Shire |
| 1.45 PM: | Opening the world of bioinformatics for biologists via biologically relevant visualization Aleksey Dubovenko, Discovery Solutions Product Manager, Clarivate Analytics |
| 2.15 PM: | Afternoon break |
| 2.30 PM: | Connecting the dots: Clarivate Analytics’ bioinformatical “big" data, human genetics, machine learning and Target ID Vlad Malkov, Biostatistician / Bioinformatician, Merck |
| 3.00 PM: | Keynote: RNAi therapeutics: Innovative experimental therapies for orphan genetic disease Kevin FitzGerald, Senior Vice President: Head of Research, Alnylam Pharmaceuticals |
| 4.00 PM: | Closing remarks Chair: Matthew Wampole, PhD, Manager, Solutions Scientists, Clarivate Analytics |
Join Clarivate Analytics CBDD program!
CBBD is a pre-competitive program focused on adoption of network analysis methods in drug development. Working together Novartis, Pfizer, Sanofi, Janssen, Regeneron, UCB, Roche, Takeda, Biogen, Boehringer Ingelheim, Bristol- Myers Squibb, Merck and Clarivate Analytics accelerate the adoption through thorough review of published systems biology algorithms, implementation of the algorithms and benchmarking.
Complete the form below to secure your place at the Systems Biology Symposium. If you need any further assistance, please do not hesitate to get in touch.
Please fill the form below.
Speakers
Kevin FitzGerald
Senior Vice President: Head of Research
Alnylam Pharmaceuticals
Matthew Wampole, PhD
Manager, Solutions Scientists
Clarivate Analytics
Abby Hill
Computational Biology Intern
Novartis
Rima Hajjo
Solution Scientist
Clarivate Analytics
Marina Bessarabova
Sr. Director, Discovery and Translational Practice
Clarivate Analytics
Kejie Li
Computational Biologist – Scientist
Biogen
Alexander Ivliev
Principal Research Scientist
Clarivate Analytics
Mindy Zhang
Principal Scientist
Sanofi Genzyme
Madhu Nataranjan
Research Therapeutic Area Head, Ophthalmics & Complement Biology
Shire
Aleksey Dubovenko
Discovery Solutions Product Manager
Clarivate Analytics
Vlad Malkov
Biostatistician / Bioinformatician
Merck
Your privacy matters
By submitting this request you are opting in to receive our emails.
Each email we send you will include the option to opt out of receiving future mailings.
View our privacy policy
Current Customers
Quick Links
Global Sites
Follow
@IPLifecycle
Clarivate Analytics
